Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qiagen ( (QGEN) ) just unveiled an announcement.
Qiagen N.V. has scheduled the publication of its 2025 annual financial report, covering the period from January 1 to December 31, 2025, for April 30, 2026. The report will be made available online under International Financial Reporting Standards, signaling the company’s ongoing disclosure to investors across its broad stock exchange listings.
The timing of the year-end report pre-announcement underscores Qiagen’s adherence to German market transparency rules and provides investors with clarity on the upcoming financial disclosure. With shares traded on major European exchanges and in the U.S. and Switzerland, the scheduled release date helps stakeholders plan around a key information event that could influence valuation and trading activity.
The most recent analyst rating on (QGEN) stock is a Hold with a $44.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V., based in Venlo, Netherlands, operates in the life sciences and diagnostics sector and is listed on multiple European exchanges as well as the NYSE and Swiss venues. The company serves global molecular testing and research markets, with its shares traded under ISIN NL0015002SN0 across regulated and free markets in Germany and on several international stock exchanges.
Average Trading Volume: 1,922,253
Technical Sentiment Signal: Sell
Current Market Cap: $7.92B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.